A review. This article discusses the regulation of the resistance of cancer cells to various therapeutics by CK2, survey drug combination data obtained with CK2 inhibitors as well as with compounds that act on the pathways regulated by CK2, and the potential of clin. development of CK2 inhibitors in combination with standards of care as well as exptl. therapeutics. Suppression of apoptosis and mechanism of PI3K-Akt-mTOR signaling, promotion of angiogenesis, Hsp90 machinery, NF-κB transcription, Wnt signaling, epithelial-mesynchemal transition and DNA damage repair are discussed.